JP4424279B2 - Photochemical medical equipment - Google Patents

Description

  The present invention relates to a photochemical medical device.

As photochemical medical devices, photochemical diagnosis (Photodynamic Diagnosis, hereinafter abbreviated as PDD) devices, photochemical therapy (Photodynamic Therapy, hereinafter abbreviated as PDT) devices, and photodiagnosis / treatment devices are known. For example, in Patent Documents 1 and 2, a photochemical diagnosis in which a photosensitizing substance having a tumor affinity is previously accumulated in a cancer lesion, and laser irradiation is performed to generate fluorescence from the photosensitive substance, thereby diagnosing the cancer lesion. An apparatus is disclosed.
Japanese Patent Publication No. 4-6389 Japanese Patent No. 2738390

  However, none of the above photochemical diagnostic apparatuses can obtain information about the depth position where the cancer lesion exists. In addition, in the case of the photochemical diagnostic apparatus described in Patent Document 1, it is difficult to diagnose when a cancer lesion is present in the deep part of the biological tissue. When there is a part, there is a problem that the observation clearness of the cancer lesion part is inferior to that of Patent Document 1, and it is difficult to obtain a highly reliable diagnosis result.

  The present invention has been made to solve the above-described problems, and an object thereof is to provide a photochemical medical device capable of obtaining a highly reliable diagnosis result and the like.

Photochemical medical device according to the present invention includes a first light emitting element emitting excitation light of a first specified wavelength lambda _p1, and a second light-emitting element emitting excitation light of a second predetermined wavelength lambda _p2, the output from the first light emitting element A first condensing lens that condenses the excitation light to be emitted, a second condensing lens that condenses the excitation light output from the second light emitting element, and the excitation light output from the first light emitting element at the incident end. A first fiber that is input and guided, and is output from the emission end; a second fiber that is input by guiding excitation light output from the second light emitting element to the incident end and is output; and a first fiber ; A third fiber that guides the generated light S generated by the excitation light output from the light emitting element and the second light emitting element, and the generated light S that is installed at one end of the third fiber and guided from the third fiber. Detection means for detecting, excitation light output from the first light emitting element and the second light emitting element. And a control unit for controlling the word, and a third light emitting element emitting therapeutic light of a specific wavelength lambda _t for treatment, and a fourth fiber for guiding a therapeutic light output from the third light emitting element, The first fiber, the second fiber, the third fiber, and the fourth fiber are bundled at the emission end, and the control unit determines that the intensity ratio S / N between the generated light S and the scattered light N of the excitation light having a specific wavelength is The power of pumping light of each specific wavelength is controlled so as to be maximum .

  In the photochemical medical device according to the present invention, it is possible to obtain at least two types of excitation light having specific wavelengths by including the first light emitting element and the second light emitting element. For this reason, excitation light of these specific wavelengths can be selected and used at the same time or optimal for diagnosis as necessary, and the performance and applicability of the apparatus can be improved and high reliability can be achieved. The diagnostic result can be obtained. Moreover, since the 1st condensing lens, the 1st optical fiber, the 2nd condensing lens, and the 2nd optical fiber which respond | correspond respectively with respect to a 1st light emitting element and a 2nd light emitting element are provided, each light emission The efficiency of optical coupling from the element to the incident end of the optical fiber can be increased. Furthermore, the excitation light output from each light emitting element is condensed by a corresponding condenser lens, is incident on the incident end of the corresponding optical fiber, is guided by the optical fiber, and is emitted from the output end of the optical fiber to the outside. Ejected efficiently. In addition, since the first fiber and the second fiber are bundled at the emission end, the pumping lights output from the first light emitting element and the second light emitting element are combined, and high power pumping light can be obtained. .

In the photochemical medical device according to the present invention, the first specific wavelength λ _p1 is in the range of 379 nm to 419 nm, the second specific wavelength λ _p2 is in the range of 634 nm to 674 nm, or the first specific wavelength λ _p1 is 379 nm to 419 nm, and the second specific wavelength λ _p2 is in the range of 610 nm to 650 nm, or the first specific wavelength λ _p1 is in the range of 660 nm to 720 nm, and the second specific wavelength λ _p2 is 770 nm to 770 nm It is preferable that it is in the range of 810 nm. In this case, if necessary, the excitation light of the first specific wavelength λ _{p1 and} the excitation light of the second specific wavelength λ _p2 can be selected simultaneously or the excitation light of the specific wavelength that is optimal for diagnosis can be selected. The performance and applicability of the apparatus can be improved, and highly reliable diagnostic results can be obtained.

  In the photochemical medical device according to the present invention, a third fiber that guides generated light S generated by irradiation of excitation light output from the first light emitting element and the second light emitting element, and one end of the third fiber It is preferable to include a detecting unit that is installed and detects the generated light S guided from the third fiber. In this case, the generated light S can be detected and the detection result can be analyzed.

  The photochemical medical device according to the present invention preferably includes a control unit that controls the power of the excitation light output from the first light emitting element and the second light emitting element. In this case, since the power of the excitation light output from the first light emitting element and the second light emitting element is controlled by the control unit, the light power can be adjusted as necessary, and the performance of the apparatus and Applicability can be improved.

  In the photochemical medical device according to the present invention, the control unit controls the power of the excitation light of each specific wavelength so that the ratio S / N between the generated light S and the scattered light N of the excitation light of the specific wavelength is maximized. It is preferable to control. In this case, since the influence of the scattered light of the excitation light can be reduced, the performance of the apparatus can be improved and the reliability of the diagnosis result can be improved.

The photochemical medical device according to the present invention includes a third light emitting element that emits therapeutic light having a specific wavelength λ _t for treatment, and a fourth fiber that guides the therapeutic light output from the third light emitting element. Is preferred. In this case, treatment can be performed simultaneously with diagnosis, and the applicability of the apparatus can be further enhanced.

  The photochemical medical device according to the present invention includes an irradiation unit that irradiates two or more different wavelengths of irradiation light on a photosensitive substance integrated in a lesion, and a control that controls the intensity ratio of each wavelength component in the irradiation light. And means for detecting at least one of an intensity change or a spectrum change of the light generated from the photosensitive substance.

  In the photochemical medical device according to the present invention, by providing an irradiation means for irradiating irradiation light having two or more different wavelengths, for example, the two or more different wavelengths depending on the characteristics of the photosensitive substance accumulated in the lesion. Can be selected at the same time or with the wavelength of light that is optimal for the characteristics of the photosensitive material, so that the performance and applicability of the device can be improved, and highly reliable diagnostic results can be obtained. can get.

  In the photochemical medical device according to the present invention, it is possible to perform diagnosis with the optimum intensity ratio of each wavelength component corresponding to the diagnosis situation by including a control unit that controls the intensity ratio of each wavelength component in the irradiation light. Therefore, the diagnosis result with higher reliability can be obtained, and the performance and applicability of the apparatus can be further enhanced.

  Furthermore, the photochemical medical device according to the present invention includes detection means for detecting at least one of the intensity change or the spectrum change of the fluorescence generated from the photosensitive substance. Therefore, these changes are detected, and the lesion is detected based on the detection result. The depth position of the part can be grasped.

  In the photochemical medical device according to the present invention, the control means changes the wavelength of the irradiation light with time, or simultaneously irradiates two or more different wavelengths and changes the intensity ratio of the irradiation light, It is preferable to control the intensity ratio of each wavelength component in the irradiation light. In these cases, it becomes possible to diagnose with the intensity ratio of each wavelength component that is optimal for the diagnosis situation, so that a highly reliable diagnosis result can be obtained and the performance and applicability of the device can be improved. Can do.

  In the photochemical medical device according to the present invention, it is preferable to include a spectroscopic means for splitting generated light. In this case, the reliability of the diagnosis result can be further improved by transmitting the generated light and blocking the scattered light of the irradiation light and other noises.

  In the photochemical medical device according to the present invention, it is preferable that the wavelength of each irradiation light corresponds to the absorption peak of the photosensitive substance. In this case, corresponding to the absorption peak of the photosensitive substance, by using each irradiation light simultaneously or properly, the diagnostic work can be facilitated and a highly reliable diagnostic result can be obtained. .

  ADVANTAGE OF THE INVENTION According to this invention, the depth position of a lesion part can be diagnosed and the photochemical medical device which can observe a lesion part clearly can be provided.

  The best mode for carrying out the present invention will be described below in detail with reference to the accompanying drawings. In the description of the drawings, the same elements are denoted by the same reference numerals, and redundant descriptions are omitted.

  FIG. 1 is a configuration diagram of a photochemical medical device 1 according to the present embodiment. As shown in FIG. 1, the photochemical medical device 1 includes a diagnostic irradiation unit 2, a detection unit 4, and a treatment irradiation unit 6.

The diagnostic irradiation unit 2 includes (1) first light emitting elements 10 that emit excitation light (that is, irradiation light) having five first specific wavelengths λ _p1 and (2) excitation of five second specific wavelengths λ _p2 . A second light emitting element 20 that emits light; (3) five first condenser lenses 12 that condense excitation light output from the first light emitting element 10; and (4) an output from the second light emitting element 20. A second condensing lens 22 for condensing the excitation light, and (5) five first light beams that are input from the excitation light output from the first light emitting element 10 to the incident end and are guided and output from the output end. The fiber 14 and (6) five second fibers 24 that are guided by inputting the excitation light output from the second light emitting element 20 to the incident end and output from the output end are in a one-to-one combination. It is configured. In addition, the diagnostic irradiation unit 2 is provided with a control unit 30 that controls the power of light output from each of the first light emitting element 10 and the second light emitting element 20. The control unit 30 includes the first specific wavelength λ _p1 and the second specific wavelength λ _p2 so that the ratio S / N between the generated light S emitted from the photosensitive substance and the scattered light N of the excitation light having the specific wavelength is maximized. The first specific wavelength λ _p1 and the second specific wavelength so as to control the power of the pump light, or to change the wavelength of the pump light with time, or to change the intensity ratio of the pump light It has a function of controlling the intensity ratio of the wavelength component of _λp2 .

The first light emitting element 10 and the second light emitting element 20 are elements that output light, and preferably include a semiconductor laser element that outputs laser light. The first specific wavelength λ _p1 emitted from the first light emitting element 10 is preferably in the range of 379 nm to 419 nm, and the second specific wavelength λ _p2 emitted from the second light emitting element 20 is preferably in the range of 634 nm to 674 nm. Further, both the first condenser lens 12 and the second condenser lens 22 have convex surfaces, and the excitation light having the first specific wavelength λ _p1 emitted from the first light emitting element 10 and the second light emitting element, respectively. 20 and the excitation light having the second specific wavelength λ _p2 emitted from 20. One end (outgoing end) of the first fiber 14 and the second fiber 24 is bundled and held by a ferrule 32, and the other ends are respectively passed through the first condenser lens 12 and the second condenser lens 22. The first light emitting element 10 and the second light emitting element 20 are optically connected.

  As shown in FIG. 1, the detection unit 4 includes one third fiber 40, a third condenser lens 42, an optical filter 44, a spectrum analyzer 46, and a monitor 48 that are sequentially connected to the third fiber 40. It consists of and. The third fiber 40 guides fluorescence S, which is generated light by irradiation of excitation light output from the first light emitting element 10 and the second light emitting element 20. One end is bundled together with the first fiber 14 and the second fiber 24 and held by the ferrule 32, and the other end is connected to the optical filter 44 via the third condenser lens 42. Further, the third condensing lens 42 has both convex surfaces like the first condensing lens 12 and the second condensing lens 22.

The optical filter 44 is used as a spectroscopic unit that splits the fluorescence S generated by the irradiation of the excitation light output from the first light emitting element 10 and the second light emitting element 20. That is, the optical filter 44 is to together to transmit fluorescence S of a specific wavelength lambda _f which is condensed from the third condenser lens 42, blocks the light of the scattered light or other wavelengths of the excitation light. As described above, the installation of the optical filter 44 can surely prevent the excitation light or the like leaking into the spectrum analyzer 46 from being misidentified as the fluorescence S, thereby improving the reliability of the diagnosis result. Instead of the optical filter 44, a spectroscope may be used.

  The spectrum analyzer 46 is connected to the optical filter 44 and detects and analyzes at least one of an intensity change or a spectrum change of the fluorescence S transmitted through the optical filter 44. The analysis result is displayed by a monitor 48 connected to the spectrum analyzer 46.

Treatment irradiation unit 6, as shown in FIG. 1, a third light emitting element 50 for emitting therapeutic light of a specific wavelength lambda _t for the treatment, for condensing the treatment beam emitted from the third light emitting element 50 first The fourth condensing lens 52 and the fourth fiber 54 for guiding the treatment light output from the third light emitting element 50 are provided. The third light emitting element 50 is preferably capable of outputting light with a specific wavelength of 400 nm to 800 nm, for example. One end of the fourth fiber 54 is bundled together with the first fiber 14, the second fiber 24, and the third fiber 40 and is held by the ferrule 32, and the other end is connected to the third light emitting element 50 via the fourth condenser lens 52. And optically connected.

  Next, PDD and PDT using the photochemical medical device 1 will be described.

  First, a photosensitive substance having two or more absorption peaks is accumulated in the cancer lesion 8. In the present embodiment, chloroline-based mono-L-aspartyl-chlorine e6 (hereinafter referred to as NPe6) is used as a photosensitive substance having two absorption peaks. As shown in FIG. 2, the absorption spectrum of NPe6 has a first peak (the highest peak) near the wavelength of 405 nm and a second peak (the second highest peak) near the wavelength of 664 nm. In addition, NPe6 is superior to photosensitizers such as hematovorphyrin derivative (HpD) in that it excretes rapidly from normal tissues and the waiting time in a dark room for suppressing sunburn is short.

Next, the diagnostic irradiation unit 2 of the photochemical medical device 1 is used to generate excitation light and irradiate the cancer lesion 8. Photosensitizer NPe6 integrated on cancerous lesion 8 is excited by irradiation of the excitation light to generate fluorescence S of a specific wavelength lambda _f. At this time, the diagnostic irradiation unit 2 includes the first light emitting element 10 that emits the excitation light having the first specific wavelength λ _p1 (that is, 379 nm to 419 nm) corresponding to the first peak of the photosensitive substance NPe6, and the second peak of NPe6. And the second light emitting element 20 that emits the excitation light having the second specific wavelength λ _p2 (that is, 634 nm to 674 nm) corresponding to the above, so that the cancer lesion 8 is in accordance with the position and depth of the living tissue. The first light emitting element 10 and the second light emitting element 20 are selectively used. For example, when the cancer lesion part 8 is near the surface of the biological tissue, excitation light in the range of 379 nm to 419 nm which is the first specific wavelength λ _p1 is used, and the cancer lesion part 8 is located deep from the surface of the biological tissue. In this case, excitation light in the range of 634 nm to 674 nm is used. Thus, by selecting and using a specific wavelength optimum for diagnosis as necessary, the diagnosis work is facilitated, and the position and range of the cancer lesion 8 can be grasped by the monitor 48. Can improve the reliability.

Moreover, it is possible to use the 1st light emitting element 10 and the 2nd light emitting element 20 simultaneously. That is, the excitation light having the first specific wavelength λ _p1 corresponding to the first peak of the photosensitive substance NPe6 and the excitation light having the second specific wavelength λ _p2 corresponding to the second peak of NPe6 are used simultaneously. In this way, a highly reliable diagnosis result can be obtained by controlling the control unit 30 to change the intensity ratio of the excitation light. For example, the first specific wavelength λ _p1 is set to 405 nm which is the first peak of the photosensitive substance NPe6, the second specific wavelength λ _p2 is set to 664 nm which is the second peak of the photosensitive substance NPe6, and the light intensity ratio of these specific wavelengths The depth of the cancer lesion part 8 in the living tissue is grasped by monitoring 48 the intensity change of the fluorescence S generated from the photosensitive substance NPe6 accumulated in the cancer lesion part 8 while controlling the time. Can do.

FIG. 3 shows that the first specific wavelength λ _p1 is 405 nm, which is the first peak of the photosensitive material NPe6, and the second specific wavelength λ _p2 is 664 nm, which is the second peak of the photosensitive material NPe6. It is a figure which shows the relationship between the light intensity ratio of a specific wavelength, and the observation clearness of the cancer lesion part 8, when changing a ratio. In the figure, Pv represents the optical power of wavelength 405 nm (first specific wavelength λ _p1 ), Pr represents the optical power of wavelength 664 nm (second specific wavelength λ _p2 ), Pf represents the power of fluorescence S, and axis as a first specific wavelength lambda _p1 between the light intensity ratio of the logarithm of the second specific wavelength lambda _p2, the light intensity of the vertical axis and the sum of the fluorescent S and first specific wavelength lambda _p1 and a second specific wavelength lambda _p2 ratio Logarithm of As shown in the figure, (1) when the depth of the cancer lesion is 0 mm (d = 0 mm) from the body surface, it is confirmed by the monitor 48 as the light intensity ratio at the wavelength of 405 nm is controlled to increase. The observational clearness of cancer lesions has been improved. (2) When the cancer lesion depth is 5 mm (d = 5 mm) from the body surface, the observation clearness of the cancer lesion is observed despite the temporal change in the light intensity ratio between the wavelength 405 nm and the wavelength 664 nm. It was kept almost constant. (3) When the cancer lesion depth is 10 mm (d = 10 mm) from the body surface, the observation clarity of the cancer lesion confirmed by the monitor 48 as the light intensity ratio at the wavelength of 664 nm is controlled to increase. Has been uploaded. Thus, the depth of the cancer lesion in the body can be estimated using the relationship between the temporal change in the light intensity ratio of the specific wavelength and the observed sharpness of the cancer lesion.

The fluorescence S generated from the photosensitive substance NPe 6 is guided by the third fiber 40 provided in the detection unit 4 of the photochemical medical device 1 and collected in the optical filter 44 through the third condenser lens 42. To be lighted. Only the fluorescence S of a specific wavelength in the optical filter 44 lambda _f is transmitted, the light of the scattered light or other wavelengths of the excitation light is blocked. The fluorescence S transmitted through the optical filter 44 is detected and analyzed by the spectrum analyzer 46 in which a spectrum change is detected. The analysis result is displayed on the monitor 48. As a result of the influence of the scattered light of the excitation light being reduced by the optical filter 44, the position and range of the cancer lesion 8 is clearly confirmed by the monitor 48, and the position and range of the cancer lesion 8 in the living tissue Can be identified.

At this time, for example, the control unit 30 of the photochemical medical device 1 causes the first specific wavelength λ so that the ratio S / N between the fluorescence S generated from the photosensitive substance NPe6 and the scattered light N of the excitation light is maximized. It is preferable to control the power of the pumping light between _p1 and the second specific wavelength _λp2 . In this way, the influence of the scattered light of the excitation light can be reduced and the reliability of the diagnosis result can be further increased.

When performing PDT based on the diagnosis result of the cancer lesion part 8, the diagnosis irradiation part 2 is stopped and switched to the treatment irradiation part 6. Specifically, the light emitting element of the diagnostic irradiation unit 2 is turned off, and the third light emitting element 50 of the treatment irradiation unit 6 is turned on. Thereby, treatment light having a specific wavelength λ _t (for example, 400 nm to 800 nm) is generated from the third light emitting element 50. Therapeutic light of a particular wavelength lambda _t is condensed by the fourth condenser lens 52, it is irradiated is guided by the fourth fiber 54 by the cancerous lesion 8. At this time, the photosensitive substance NPe6 accumulated in the cancer lesion part 8 generates active oxygen such as singlet oxygen by irradiation with the treatment light, thereby treating the cancer lesion part 8 due to the cell killing effect.

Next, PDD and PDT are repeated. That is, the treatment irradiation unit 6 is stopped and the diagnosis irradiation unit 2 and the detection unit 4 are switched to confirm the treatment result of the cancer lesion unit 8, and the diagnosis irradiation unit 2 is stopped and the treatment irradiation unit 6 is switched to the cancer lesion unit. 8 is treated. For this reason, diagnosis and treatment of the cancer lesion 8 can be performed. In addition, as described above, the depth of the cancer lesion part 8 in the living tissue can be grasped by using the relationship between the temporal change in the light intensity ratio of the specific wavelength and the observation sharpness of the cancer lesion part 8. Therefore, a highly reliable treatment effect can be obtained by adjusting the power of the treatment light having the specific wavelength λ _t according to the depth of the cancer lesion portion 8.

  According to the present invention, the photochemical medical device 1 includes the first light emitting element 10 and the second light emitting element 20, thereby obtaining excitation light of two types of specific wavelengths. For this reason, if necessary, the two types of excitation light can be used at the same time, or the two types of excitation light can be selectively used to select and use the optimum excitation light for diagnosis, facilitating the diagnosis work. And a highly reliable diagnostic result can be obtained. Then, the power of the excitation light of each specific wavelength is set so that the ratio S / N between the fluorescence S emitted from the photosensitive substance NPe6 used for diagnosis by the control unit 30 and the scattered light N of the excitation light of the specific wavelength is maximized. Noise such as scattering of excitation light by controlling or controlling the intensity ratio of each wavelength component so as to change the wavelength of each excitation light with time, or to change the intensity ratio of each excitation light Thus, the reliability of the diagnosis result can be further improved, and the performance and applicability of the apparatus can be improved. Furthermore, since the treatment irradiation unit 6 for treating simultaneously with the diagnosis is provided, the applicability of the apparatus can be further enhanced.

  Further, the photochemical medical device 1 includes a first condensing lens 12, a first optical fiber 14 and a second condensing lens 22 corresponding to the first light emitting element 10 and the second light emitting element 20, respectively. Since the optical fiber 24 is provided, the efficiency of optical coupling from each light emitting element to the incident end of the optical fiber can be increased. Therefore, the excitation light output from each light emitting element is condensed by the corresponding condenser lens, is incident on the incident end of the corresponding optical fiber, is guided by the optical fiber, and is externally transmitted from the output end of the optical fiber. Is efficiently emitted.

  In addition, since the first fiber 14 and the second fiber 24 are bundled at the emission end, the excitation lights output from the first light emitting element 10 and the second light emitting element 20 are combined, and high power excitation light is generated. The effect which improves the performance and reliability of the photochemical medical device 1 can be expected. Further, the first fiber 14, the second fiber 24, the third fiber 40, and the fourth fiber 54 are bundled at the emission ends of the first fiber 14 and the second fiber 24, thereby manufacturing the photochemical medical device 1. In doing so, workability can be improved. In addition, the use of a semiconductor light emitting element can reduce the size and cost of the apparatus as compared with the case where an excimer laser or the like is used. Here, as a method of bundling the first fiber 14 and the second fiber 24, as well as the third fiber 40 and the fourth fiber 54, a plurality of optical fibers that are inserted and fixed into the ferrule 32 are fixed. Fixing each other with an adhesive or melting and bundling optical fibers.

As the photosensitizer, Photofin, Indocyanine green, etc. can be used in addition to mono-L-aspartyl-chlorine e6 (NPe6) described in the above description. In the case of Photofin is, λ _p1 = 379nm~419nm, and λ _p2 = 610nm~650nm, in the case of Indocyanine green is, λ _p1 = 660nm~720nm, and λ _p2 = 770nm~810nm, and examples of the above case NPe6 Similar effects can be obtained with the same configuration and method. Of course, other photosensitive substances having two or more absorption peaks may be used. In addition, these substances can be accumulated in all tumors regardless of benign or malignant, and the present invention can be applied to other than the cancer lesion.

For the wavelengths λ _p1 and λ _p2 to be used, the depth position of the lesion should be different from the living tissue depth depth (depth at which the light intensity attenuates 1 / e times when the tissue is irradiated with light). This is desirable for diagnosis. For example, biological tissue invasion length of the light lambda _p1 1 mm or less, lambda biological tissue invasion length of light _p2 is preferably at 3mm or more. In general, cancer lesions tend to occur relatively near the surface layer in early cancers, while cancer lesions grow relatively deep in tissues in advanced cancers. By irradiating λ _p1 and λ _p2 having different biological tissue depths at two excitation light wavelengths, it is possible to deal with a wider range in the depth direction, and further, λ _p1 , λ _p2 , By comparing the areas of the fluorescence distribution when each is irradiated, the progress of cancer can also be grasped. For example, when the area of the fluorescence distribution of both does not change significantly, it can be predicted that the cancer is an early stage cancer that exists only on the surface layer, whereas the area of the fluorescence distribution when irradiated with λ _p2 is compared with that when irradiated with λ _p1 If it is wide, it can be expected that it has proliferated to the deep part of the tissue.

  The photochemical medical device 1 is a device that can perform photochemical diagnosis and photochemical treatment, but may be a device that can perform only photochemical diagnosis or only photochemical treatment depending on medical purposes.

  The present invention is not limited to the above embodiment. In the above embodiment, the number of the light emitting elements, the condensing lenses, and the fibers of the diagnostic irradiation unit 2 is five, the number of the fibers and the condensing lenses of the detection unit 4 is one, and the treatment irradiation unit. Although the number of the light emitting elements 6, the condensing lens, and the fiber is one for each, the number is not limited to this, and the number may be changed as necessary.

It is a block diagram of the light source device which concerns on embodiment. It is a figure which shows the absorption peak of the photosensitive substance mono-L-aspartyl-chlorine e6 (NPe6). It is a figure which shows the relationship between the light intensity ratio of a specific wavelength, and the observation clearness of a cancer lesion part.

Explanation of symbols

  DESCRIPTION OF SYMBOLS 1 ... Photochemical medical device, 8 ... Cancer lesion part, 10 ... 1st light emitting element, 12 ... 1st condensing lens, 14 ... 1st fiber, 20 ... 2nd light emitting element, 22 ... 2nd condensing lens, 24 ... 2nd fiber, 30 ... Control part, 40 ... 3rd fiber, 44 ... Optical filter, 46 ... Spectrum analyzer, 50 ... 3rd light emitting element, 54 ... 4th fiber.

Claims (4)

A first light emitting element that emits excitation light having a first specific wavelength λ _p1 ;
A second light emitting element that emits excitation light having a second specific wavelength λ _p2 ;
A first condenser lens for condensing excitation light output from the first light emitting element;
A second condenser lens that condenses the excitation light output from the second light emitting element;
A first fiber that inputs and guides excitation light output from the first light emitting element to an incident end, and outputs from the output end;
A second fiber that inputs and guides the excitation light output from the second light emitting element to the incident end and outputs from the output end ;
A third fiber for guiding the generated light S generated by the excitation light output from the first light emitting element and the second light emitting element;
Detecting means for detecting the generated light S installed at one end of the third fiber and guided from the third fiber;
A control unit for controlling the power of excitation light output from the first light emitting element and the second light emitting element;
A third light emitting element that emits treatment light having a specific wavelength λ _t for treatment;
A fourth fiber for guiding treatment light output from the third light emitting element;
With
The first fiber, the second fiber, the third fiber, and the fourth fiber are bundled at the exit end ;
The control unit controls the power of the excitation light of each specific wavelength so that the intensity ratio S / N between the generated light S and the scattered light N of the excitation light of the specific wavelength is maximized. Photochemical medical device. Wherein the first specific wavelength lambda _p1 is in the range of 379Nm～419nm, the second specific wavelength lambda _p2 photochemical medical device according to claim 1, characterized in that the range of 634Nm～674nm. 2. The photochemical medical device according to claim 1, wherein the first specific wavelength λ _p1 is in a range of 379 nm to 419 nm, and the second specific wavelength λ _p2 is in a range of 610 nm to 650 nm. Wherein the first specific wavelength lambda _p1 is in the range of 660Nm～720nm, the second specific wavelength lambda _p2 photochemical medical device according to claim 1, characterized in that the range of 770Nm～810nm.

Images